Work

P2.06-05 Durvalumab ± Tremelimumab + Chemotherapy in 1L Metastatic NSCLC: Characterisation of patients with PFS ≥12 months in POSEIDON

Year: 2023

Type: article

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2023.09.551

Authors: B.C. Cho, I. Diaz Perez, C. Lowery, L. Szadkowski, S. Peters, E.B. Garon, T. Mok, M.L. Johnson

Institutions: Yonsei Cancer Hospital, AstraZeneca (United States), AstraZeneca (Canada), Centre Hospitalier Universitaire Vaudois, University of California, Los Angeles, Chinese University of Hong Kong, Sarah Cannon, Tennessee Oncology

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4388045306

FWCI:

Cites:

Cited by:

Related to: 10